A translational continuum of model systems for evaluating treatment strategies in Alzheimer’s disease: isradipine as a candidate drug
SUMMARY A growing body of evidence supports the ‘calcium hypothesis’ of Alzheimer’s disease (AD), which postulates that a variety of insults might disrupt the homeostatic regulation of neuronal calcium (Ca2+) in the brain, resulting in the progressive symptoms that typify the disease. However, despi...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
The Company of Biologists
2011-09-01
|
Series: | Disease Models & Mechanisms |
Online Access: | http://dmm.biologists.org/content/4/5/634 |
id |
doaj-f3342a8f76b14e7092495bbbacfb9461 |
---|---|
record_format |
Article |
spelling |
doaj-f3342a8f76b14e7092495bbbacfb94612020-11-25T01:13:41ZengThe Company of BiologistsDisease Models & Mechanisms1754-84031754-84112011-09-014563464810.1242/dmm.006841006841A translational continuum of model systems for evaluating treatment strategies in Alzheimer’s disease: isradipine as a candidate drugPhilip F. CopenhaverThimmappa S. AnekondaDerek MusasheKristine M. RobinsonJenna M. RamakerTracy L. SwansonTeri L. WadsworthDoris KretzschmarRandall L. WoltjerJoseph F. QuinnSUMMARY A growing body of evidence supports the ‘calcium hypothesis’ of Alzheimer’s disease (AD), which postulates that a variety of insults might disrupt the homeostatic regulation of neuronal calcium (Ca2+) in the brain, resulting in the progressive symptoms that typify the disease. However, despite ongoing efforts to develop new methods for testing therapeutic compounds that might be beneficial in AD, no single bioassay permits both rapid screening and in vivo validation of candidate drugs that target specific components of the Ca2+ regulatory machinery. To address this issue, we have integrated four distinct model systems that provide complementary information about a trial compound: the human neuroblastoma MC65 line, which provides an in vitro model of amyloid toxicity; a transgenic Drosophila model, which develops age-dependent pathologies associated with AD; the 3×TgAD transgenic mouse, which recapitulates many of the neuropathological features that typify AD; and the embryonic nervous system of Manduca, which provides a novel in vivo assay for the acute effects of amyloid peptides on neuronal motility. To demonstrate the value of this ‘translational suite’ of bioassays, we focused on a set of clinically approved dihydropyridines (DHPs), a class of well-defined inhibitors of L-type calcium channels that have been suggested to be neuroprotective in AD. Among the DHPs tested in this study, we found that isradipine reduced the neurotoxic consequences of β-amyloid accumulation in all four model systems without inducing deleterious side effects. Our results provide new evidence in support of the Ca2+ hypothesis of AD, and indicate that isradipine represents a promising drug for translation into clinical trials. In addition, these studies also demonstrate that this continuum of bioassays (representing different levels of complexity) provides an effective means of evaluating other candidate compounds that target specific components of the Ca2+ regulatory machinery and that therefore might be beneficial in the treatment of AD.http://dmm.biologists.org/content/4/5/634 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Philip F. Copenhaver Thimmappa S. Anekonda Derek Musashe Kristine M. Robinson Jenna M. Ramaker Tracy L. Swanson Teri L. Wadsworth Doris Kretzschmar Randall L. Woltjer Joseph F. Quinn |
spellingShingle |
Philip F. Copenhaver Thimmappa S. Anekonda Derek Musashe Kristine M. Robinson Jenna M. Ramaker Tracy L. Swanson Teri L. Wadsworth Doris Kretzschmar Randall L. Woltjer Joseph F. Quinn A translational continuum of model systems for evaluating treatment strategies in Alzheimer’s disease: isradipine as a candidate drug Disease Models & Mechanisms |
author_facet |
Philip F. Copenhaver Thimmappa S. Anekonda Derek Musashe Kristine M. Robinson Jenna M. Ramaker Tracy L. Swanson Teri L. Wadsworth Doris Kretzschmar Randall L. Woltjer Joseph F. Quinn |
author_sort |
Philip F. Copenhaver |
title |
A translational continuum of model systems for evaluating treatment strategies in Alzheimer’s disease: isradipine as a candidate drug |
title_short |
A translational continuum of model systems for evaluating treatment strategies in Alzheimer’s disease: isradipine as a candidate drug |
title_full |
A translational continuum of model systems for evaluating treatment strategies in Alzheimer’s disease: isradipine as a candidate drug |
title_fullStr |
A translational continuum of model systems for evaluating treatment strategies in Alzheimer’s disease: isradipine as a candidate drug |
title_full_unstemmed |
A translational continuum of model systems for evaluating treatment strategies in Alzheimer’s disease: isradipine as a candidate drug |
title_sort |
translational continuum of model systems for evaluating treatment strategies in alzheimer’s disease: isradipine as a candidate drug |
publisher |
The Company of Biologists |
series |
Disease Models & Mechanisms |
issn |
1754-8403 1754-8411 |
publishDate |
2011-09-01 |
description |
SUMMARY
A growing body of evidence supports the ‘calcium hypothesis’ of Alzheimer’s disease (AD), which postulates that a variety of insults might disrupt the homeostatic regulation of neuronal calcium (Ca2+) in the brain, resulting in the progressive symptoms that typify the disease. However, despite ongoing efforts to develop new methods for testing therapeutic compounds that might be beneficial in AD, no single bioassay permits both rapid screening and in vivo validation of candidate drugs that target specific components of the Ca2+ regulatory machinery. To address this issue, we have integrated four distinct model systems that provide complementary information about a trial compound: the human neuroblastoma MC65 line, which provides an in vitro model of amyloid toxicity; a transgenic Drosophila model, which develops age-dependent pathologies associated with AD; the 3×TgAD transgenic mouse, which recapitulates many of the neuropathological features that typify AD; and the embryonic nervous system of Manduca, which provides a novel in vivo assay for the acute effects of amyloid peptides on neuronal motility. To demonstrate the value of this ‘translational suite’ of bioassays, we focused on a set of clinically approved dihydropyridines (DHPs), a class of well-defined inhibitors of L-type calcium channels that have been suggested to be neuroprotective in AD. Among the DHPs tested in this study, we found that isradipine reduced the neurotoxic consequences of β-amyloid accumulation in all four model systems without inducing deleterious side effects. Our results provide new evidence in support of the Ca2+ hypothesis of AD, and indicate that isradipine represents a promising drug for translation into clinical trials. In addition, these studies also demonstrate that this continuum of bioassays (representing different levels of complexity) provides an effective means of evaluating other candidate compounds that target specific components of the Ca2+ regulatory machinery and that therefore might be beneficial in the treatment of AD. |
url |
http://dmm.biologists.org/content/4/5/634 |
work_keys_str_mv |
AT philipfcopenhaver atranslationalcontinuumofmodelsystemsforevaluatingtreatmentstrategiesinalzheimersdiseaseisradipineasacandidatedrug AT thimmappasanekonda atranslationalcontinuumofmodelsystemsforevaluatingtreatmentstrategiesinalzheimersdiseaseisradipineasacandidatedrug AT derekmusashe atranslationalcontinuumofmodelsystemsforevaluatingtreatmentstrategiesinalzheimersdiseaseisradipineasacandidatedrug AT kristinemrobinson atranslationalcontinuumofmodelsystemsforevaluatingtreatmentstrategiesinalzheimersdiseaseisradipineasacandidatedrug AT jennamramaker atranslationalcontinuumofmodelsystemsforevaluatingtreatmentstrategiesinalzheimersdiseaseisradipineasacandidatedrug AT tracylswanson atranslationalcontinuumofmodelsystemsforevaluatingtreatmentstrategiesinalzheimersdiseaseisradipineasacandidatedrug AT terilwadsworth atranslationalcontinuumofmodelsystemsforevaluatingtreatmentstrategiesinalzheimersdiseaseisradipineasacandidatedrug AT doriskretzschmar atranslationalcontinuumofmodelsystemsforevaluatingtreatmentstrategiesinalzheimersdiseaseisradipineasacandidatedrug AT randalllwoltjer atranslationalcontinuumofmodelsystemsforevaluatingtreatmentstrategiesinalzheimersdiseaseisradipineasacandidatedrug AT josephfquinn atranslationalcontinuumofmodelsystemsforevaluatingtreatmentstrategiesinalzheimersdiseaseisradipineasacandidatedrug AT philipfcopenhaver translationalcontinuumofmodelsystemsforevaluatingtreatmentstrategiesinalzheimersdiseaseisradipineasacandidatedrug AT thimmappasanekonda translationalcontinuumofmodelsystemsforevaluatingtreatmentstrategiesinalzheimersdiseaseisradipineasacandidatedrug AT derekmusashe translationalcontinuumofmodelsystemsforevaluatingtreatmentstrategiesinalzheimersdiseaseisradipineasacandidatedrug AT kristinemrobinson translationalcontinuumofmodelsystemsforevaluatingtreatmentstrategiesinalzheimersdiseaseisradipineasacandidatedrug AT jennamramaker translationalcontinuumofmodelsystemsforevaluatingtreatmentstrategiesinalzheimersdiseaseisradipineasacandidatedrug AT tracylswanson translationalcontinuumofmodelsystemsforevaluatingtreatmentstrategiesinalzheimersdiseaseisradipineasacandidatedrug AT terilwadsworth translationalcontinuumofmodelsystemsforevaluatingtreatmentstrategiesinalzheimersdiseaseisradipineasacandidatedrug AT doriskretzschmar translationalcontinuumofmodelsystemsforevaluatingtreatmentstrategiesinalzheimersdiseaseisradipineasacandidatedrug AT randalllwoltjer translationalcontinuumofmodelsystemsforevaluatingtreatmentstrategiesinalzheimersdiseaseisradipineasacandidatedrug AT josephfquinn translationalcontinuumofmodelsystemsforevaluatingtreatmentstrategiesinalzheimersdiseaseisradipineasacandidatedrug |
_version_ |
1725160705846411264 |